COLO B Coloplast A/S Class B

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.

The below transactions concern allocation of share options.

For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:





  Details of the person discharging managerial responsibilities/person closely associated
a) Name Kristian Villumsen
2 Reason for the notification
a) Position/status President & CEO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 73,690
d) Aggregated information  
-        Aggregated volume 73,690 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Anders Lonning-Skovgaard
2 Reason for the notification
a) Position/status Executive Vice President & CFO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 37,511
d) Aggregated information  
-        Aggregated volume 37,511 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue

  

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Vice President, Investor Relations

Tel. /

Email:

Simone Dyrby Helvind

Senior Manager, Investor Relations

Tel. /

Email:

Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-02.



All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
04/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conferenc...

Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the ...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den k...

Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Selskabsmeddelelse nr. 09/2025Intern viden Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Interim CEO Lars Rasmussen har i dag informeret Coloplasts bestyrelse om, at han ikke genopstiller som bestyrelsesmedlem ved den kommende ordinære generalforsamling den 4. december 2025. ”På vegne af bestyrelsen vil jeg gerne takke Lars for hans mangeårige engagement i Coloplast. Gennem næsten fire årtiers virke – herunder 10 år som CEO og...

 PRESS RELEASE

Coloplast interim CEO Lars Rasmussen will step down from the Board at ...

Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Announcement no. 09/2025Inside information   Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting  Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025.   “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch